The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the ...

Check the time stamp on this data. Updated AI-Generated Signals for Biontech Se (BNTX) available here: BNTX. Type a few ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...